On December 14th, 2011, The Nebraska Heart Institute Heart Valve Team successfully performed the first two commercial cases to replace a patient’s aortic valve without utilizing traditional open-heart surgery. The Transcatheter Aortic Valve Replacement (TAVR) procedure was performed at the Nebraska Heart Hospital (NHH) in Lincoln, Neb.
NHH is one of the first hospitals in the United States to treat patients with the recently FDA-approved Edwards SAPIEN Transcatheter Heart Valve. The Edwards device was approved this past November, 2011 by the U.S. Food and Drug Administration as a therapy for patients with severe symptomatic native aortic valve stenosis who have been determined by a cardiac surgeon to be inoperable for open aortic valve replacement and in whom existing co-morbidities would not preclude the expected benefit from correction of the aortic stenosis (AS).
Up to 1.5 million people in the U.S. suffer from AS, with an estimated 250,000 patients having severe AS. Studies show that without an aortic valve replacement, more than 50 percent of patients with severe AS will not survive more than an average of two years after onset of symptoms.
This Thursday, February 16, the Nebraska Heart Institute Heart Team (surgeons, cardiologists and clinical staff) will be available to discuss this innovative procedure and how a multi-disciplinary team approach is essential to ensuring optimal patient outcomes. Additionally, one of the first patients to receive the device will be present to share his personal story.
Nebraska Heart TAVR Press Conference:
Thursday, February 16, 2012
Nebraska Heart Campus
7440 South 91st
Medical Office Building Classroom 1
For Information, contact:
J Hoffman, 402-450-2558; email@example.com
Nebraska Heart Institute & Heart Hospital